Alpitatug
Based on 1 Customer Validation
Alpitatug (IMC 3C5) is a fully human monoclonal antibody and also a VEGFR3 inhibitor. Alpitatug blocks renal lymphangiogenesis, prevents the formation of tubulointerstitial lymphatic vessels, and reduces the number of lymphatic vessels in rats. Alpitatug does not alter the proteinuria level, inflammatory cell infiltration, fibrosis markers or renal function parameters in proteinuric rats. Alpitatug can be used in research related to proteinuric nephropathy and advanced solid tumors.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.13%
- CAS 番号: 2921676-05-1
- 分子量:145.30 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
KLK2/Kallikrein 2
体内実験
Alpitatug (40 mg/kg; i.p.; three times per week; 6 weeks) significantly reduces lymphatic vessel number in healthy male Wistar rats without impacting renal inflammatory or fibrotic markers[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (3-month-old male, 180-200 g, chronic kidney disease induced by single tail vein injection of 1.8 mg/kg adriamycin)[1]
-
Dosage:40 mg/kg
-
Administration:i.p.; three times per week; 6 weeks
-
Result:Completely prevented tubulointerstitial lymphatic vessel formation in proteinuric rats, with a significant reduction in mean LV number compared to untreated proteinuric rats (P<0.001).
Reduced LV number in healthy treated rats compared to untreated healthy controls (P<0.001).
Showed no significant changes in proteinuria, body weight, blood pressure, heart rate, food/fluid intake, or creatinine clearance compared to untreated proteinuric rats.
Exhibited a non-significant trend toward reduced ED1-positive macrophages, no marked change in CD3-positive T-cell number, and no significant effects on α-SMA-positive myofibroblast accumulation, collagen III deposition, or interstitial fibrosis (PAS staining score).
Showed a near-significant reduction in collagen III (α1) mRNA expression, but no significant effects on collagen I (α1), TGF-β1, VCAM-1, MCP-1/CCL2, or osteopontin mRNA expression.
Showed no significant differences in total white blood count, lymphocytes, neutrophils, basophils, or eosinophils.
-
Animal Model:Wistar rats (3-month-old male, 180-200 g, healthy)[1]
-
Dosage:40 mg/kg
-
Administration:i.p.; three times per week; 6 weeks
-
Result:Significantly reduced mean LV number in healthy rats compared to untreated healthy controls (P<0.001).
Showed no significant changes in body weight, blood pressure, heart rate, food/fluid intake, or creatinine clearance compared to untreated healthy rats.
Exhibited a non-significant trend toward reduced ED1-positive macrophages, no marked change in CD3-positive T-cell number, and no significant effects on α-SMA-positive myofibroblast accumulation, collagen III deposition, or interstitial fibrosis (PAS staining score).
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG1-kappa
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human Kallikrein can bind Alpitatug. The EC50 for this effect is 227.9 ng/mL. -
Flow cytometric analysis of 1.5×106 HT-29 cells with Alpitatug (HY-P990608, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
化学情報
-
CAS 番号 2921676-05-1
-
性状 Liquid
-
分子量 145.30 kDa
-
Color Colorless to light yellow
-
別名
IMC 3C5; JNJ-69086420 antibody; Anti-KLK2 Antibody (h11B6)
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)